Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.91 |
| ▸ | DRD1 | P21728 | 1/20 | 0.91 |
| ▸ | LMNA | P02545 | 2/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.84 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.78 |
| ▸ | BCHE | P06276 | 1/20 | 0.74 |
| ▸ | ACHE | P22303 | 1/20 | 0.74 |
| ▸ | DRD4 | P21917 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Laudanidine SCHEMBL8364878 | 1.00 | DRD2 (0.91) | DRD2DRD1LMNAKDM4EALDH1A1 | |
| Laudanidine SCHEMBL679496 | 1.00 | DRD2 (0.91) | DRD2DRD1LMNAKDM4EALDH1A1 | |
| Laudanidine SCHEMBL15696580 | 1.00 | DRD2 (0.91) | DRD2DRD1LMNAKDM4EALDH1A1 | |
| Laudanidine SCHEMBL30589210 | 1.00 | DRD2 (0.91) | DRD2DRD1LMNAKDM4EALDH1A1 | |
| Laudanidine SCHEMBL18187574 | 0.98 | DRD2 (0.95) | DRD2DRD1LMNAKDM4EALDH1A1 | |
| (S)-Reticuline SCHEMBL147597 | 0.95 | DRD2 (1.00) | DRD2DRD1LMNAKDM4EALDH1A1 | |
| (R)-Reticuline SCHEMBL29364903 | 0.95 | DRD2 (1.00) | DRD2DRD1LMNAKDM4EALDH1A1 | |
| (S)-Reticuline SCHEMBL147596 | 0.95 | DRD2 (1.00) | DRD2DRD1LMNAKDM4EALDH1A1 | |
| SCHEMBL29376236 | 0.95 | DRD2 (0.91) | DRD2DRD1LMNAKDM4EALDH1A1 | |
| (S)-Reticuline SCHEMBL29923953 | 0.95 | DRD2 (1.00) | DRD2DRD1LMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299481-A1 | STEPHANIA CEPHARANTHA-DERIVED ALKALOID-CONTAINING PREPARATION | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 2024-09-12 | — | — | US | claimed |
| US-20190352618-A1 | MORPHINAN N-DEMETHYLASE ISOLATED FROM THE METHYLOBACTERIUM THEBAINFRESSER AND METHODS OF USE THEREOF | DONALD DANFORTH PLANT SCIENCE CENTER | 2019-11-21 | — | — | US | claimed |
| WO-2018136654-A1 | MORPHINAN N-DEMETHYLASE ISOLATED FROM THE METHYLOBACTERIUM THEBAINFRESSER AND METHODS OF USE THEREOF | DONALD DANFORTH PLANT SCIENCE CENTER (US) | 2018-07-26 | — | — | WO | claimed |
| US-20160184232-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.) | 2016-06-30 | — | — | US | claimed |
| US-20130273153-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2013-10-17 | — | — | US | claimed |
| US-20110287095-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | Mallinkckrodt Inc. (US) | 2011-11-24 | — | — | US | claimed |
| WO-2011087765-A2 | METHODS OF PRODUCING STABILIZED SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING MORPHINANS | MALLINCKRODT INC. (US) | 2011-07-21 | — | — | WO | claimed |
| US-20110150989-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | Mallinkckrodt Inc. (US) | 2011-06-23 | — | — | US | claimed |
| US-20110077222-A1 | Sustained-Release Opiate and Opiate Derivative Compositions | MALLINCKRODT INC. (US) | 2011-03-31 | — | — | US | claimed |
| US-6123943-A | ADMINISTERING TO A VERTEBRATE A COMPOUND SELECTED FROM THE GROUP CONTAINING ALKALOIDS OBTAINABLE FROM A PLANT BELONGING TO GENUS STEPHANIA OF THE FAMILY MENSPEMACEAE FREE OF CEPHARANTHINE FOR INHIBITING NUCLEAR FACTOR KAPPA-B ACTIVITY | KAKEN SHOYAKU CO., LTD. (JP) | 2000-09-26 | — | — | US | claimed |
| EP-0931544-A2 | NF-kB activity inhibitor | Kaken Shoyaku Co., Ltd. (JP) | 1999-07-28 | — | — | EP | claimed |
| CN-120060186-A | Enzyme activity-improved oxhide alkali 7-O-methyltransferase mutant and application thereof | 浙江中医药大学 | 2025-05-30 | — | — | CN | disclosed |
| EP-4434521-A1 | STEPHANIA CEPHALANTHA-DERIVED ALKALOID-CONTAINING PREPARATION | Japan As Represented By Director-General Of National Institute Of Infectious Diseases (JP) | 2024-09-25 | — | — | EP | disclosed |
| US-20240299481-A1 | STEPHANIA CEPHARANTHA-DERIVED ALKALOID-CONTAINING PREPARATION | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 2024-09-12 | — | — | US | disclosed |
| CN-118555958-A | Preparation containing alkaloid from Anoectochilus formosanus | 国立感染症研究所所长代表的日本国 | 2024-08-27 | — | — | CN | disclosed |
| US-20050257295-A1 | Production of reticuline | FIST ANTHONY J | 2005-11-17 | — | — | US | disclosed |
| WO-2005053382-A1 | MODULATION OF CYTOCHROME P-450 REDUCTASE ACTIVITY IN POPPY PLANTS | JOHNSON & JOHNSON RESEARCH PTY LIMITED (AU) | 2005-06-16 | — | — | WO | disclosed |
| US-6123943-A | ADMINISTERING TO A VERTEBRATE A COMPOUND SELECTED FROM THE GROUP CONTAINING ALKALOIDS OBTAINABLE FROM A PLANT BELONGING TO GENUS STEPHANIA OF THE FAMILY MENSPEMACEAE FREE OF CEPHARANTHINE FOR INHIBITING NUCLEAR FACTOR KAPPA-B ACTIVITY | KAKEN SHOYAKU CO., LTD. (JP) | 2000-09-26 | — | — | US | disclosed |
| EP-0931544-A2 | NF-kB activity inhibitor | Kaken Shoyaku Co., Ltd. (JP) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999035902-A1 | IMPROVED PRODUCTION OF RETICULINE | TASMANIAN ALKALOIDS PTY. LTD. (AU) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150989-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | DRD2 1084/4885DRD1 963/4885LMNA 520/4885 |
| US-20110287095-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | DRD2 1084/4885DRD1 963/4885LMNA 520/4885 |
| US-20110077222-A1 | Sustained-Release Opiate and Opiate Derivative Compositions | OPRL1, OPRK1, OPRM1 | DRD2 85/4885DRD1 213/4885LMNA 4742/4885 |
| US-20240299481-A1 | STEPHANIA CEPHARANTHA-DERIVED ALKALOID-CONTAINING PREPARATION | SARS1, BCDIN3D, CCL5 | DRD2 2333/4885DRD1 2338/4885LMNA 3385/4885 |
| US-20130273153-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | DRD2 1084/4885DRD1 963/4885LMNA 520/4885 |
| US-20160184232-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | DRD2 1084/4885DRD1 963/4885LMNA 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.